ABL Bio Inc
KOSDAQ:298380
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Spacenet Enterprises India Ltd
NSE:SPCENET
|
IN |
|
Kawata Mfg. Co Ltd
TSE:6292
|
JP |
|
Apeejay Surrendra Park Hotels Ltd
NSE:PARKHOTELS
|
IN |
|
R
|
Riga Sugar Co Ltd
BSE:507508
|
IN |
|
A Metaverse Co
HKEX:1616
|
CN |
ABL Bio Inc
Total Current Assets
ABL Bio Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Current Assets
₩176.1B
|
CAGR 3-Years
30%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Current Assets
₩6.2T
|
CAGR 3-Years
28%
|
CAGR 5-Years
20%
|
CAGR 10-Years
19%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Total Current Assets
₩1.2T
|
CAGR 3-Years
-11%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Total Current Assets
₩140.9B
|
CAGR 3-Years
29%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Total Current Assets
₩56.5B
|
CAGR 3-Years
45%
|
CAGR 5-Years
102%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Current Assets
₩480.8B
|
CAGR 3-Years
49%
|
CAGR 5-Years
28%
|
CAGR 10-Years
34%
|
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Total Current Assets?
Total Current Assets
176.1B
KRW
Based on the financial report for Dec 31, 2025, ABL Bio Inc's Total Current Assets amounts to 176.1B KRW.
What is ABL Bio Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
20%
Over the last year, the Total Current Assets growth was 22%. The average annual Total Current Assets growth rates for ABL Bio Inc have been 30% over the past three years , 20% over the past five years .
